Optimizing the delivery of cancer drugs that block angiogenesis

Science Translational Medicine

Volumn 2, Issue 15, 2010, Pages

  Cao, Yihai ^a   Langer, Robert ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; ETHYLENE VINYL ACETATE COPOLYMER; FUMAGILLOL CHLOROACETYLCARBAMATE; SORAFENIB; SUNITINIB;

ADRENAL HEMORRHAGE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; HUMAN; HYPERTENSION; LIPOSOMAL DELIVERY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77952581069     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000399     Document Type: Review

References (47)

1. M. S. O'Reilly, L. Holmgren, Y. Shing, C. Chen, R. A. Rosenthal, M. Moses, W. S. Lane, Y. Cao, E. H. Sage, J. Folkman, Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994).
2. Y. Cao, W. Zhong, Y. Sun, Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin. Cancer Biol. 19, 338-343 (2009).
3. M. R. Mancuso, R. Davis, S. M. Norberg, S. O'Brien, B. Sennino, T. Nakahara, V. J. Yao, T. Inai, P. Brooks, B. Freimark, D. R. Shalinsky, D. D. Hu-Lowe, D. M. McDonald, Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610-2621 (2006).
4. J. Folkman, Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
5. R. Langer, H. Brem, K. Falterman, M. Klein, J. Folkman, Isolations of a cartilage factor that inhibits tumor neo-vascularization. Science 193, 70-72 (1976).
6. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
7. C. G. Willett, Y. Boucher, E. di Tomaso, D. G. Duda, L. L. Munn, R. T. Tong, D. C. Chung, D. V. Sahani, S. P. Kalva, S. V. Kozin, M. Mino, K. S. Cohen, D. T. Scadden, A. C. Hartford, A. J. Fischman, J. W. Clark, D. P. Ryan, A. X. Zhu, L. S. Blaszkowsky, H. X. Chen, P. C. Shellito, G. Y. Lauwers, R. K. Jain, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular eff ects in human rectal cancer. Nat. Med. 10, 145-147 (2004).
8. J. Folkman, Angiogenesis: An organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286 (2007). (Pubitemid 46505878)
9. F. Bertolini, P. Mancuso, Y. Shaked, R. S. Kerbel, Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov. Today 12, 806-812 (2007).
10. R. K. Jain, D. G. Duda, C. G. Willett, D. V. Sahani, A. X. Zhu, J. S. Loeffler, T. T. Batchelor, A. G. Sorensen, Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol 6, 327-338 (2009).
11. J. M. Ebos, C. R. Lee, E. Bogdanovic, J. Alami, P. Van Slyke, G. Francia, P. Xu, A. J. Mutsaers, D. J. Dumont, R. S. Kerbel, Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res. 68, 521-529 (2008).
12. Y. Xue, P. Religa, R. Cao, A. J. Hansen, F. Lucchini, B. Jones, Y. Wu, Z. Zhu, B. Pytowski, Y. Liang, W. Zhong, P. Vezzoni, B. Rozell, Y. Cao, Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc. Natl. Acad. Sci. U.S.A. 105, 18513-18518 (2008).
13. R. Langer, Drug delivery and targeting. Nature 392 (suppl.), 5-10 (1998).
14. J. M. Ebos, C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, R. S. Kerbel, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
15. M. Pàez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, F. Viñals, M. Inoue, G. Bergers, D. Hanahan, O. Casanovas, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
16. O. Casanovas, D. J. Hicklin, G. Bergers, D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
17. S. Loges, M. Mazzone, P. Hohensinner, P. Carmeliet, Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15, 167-170 (2009).
18. G. Bergers, D. Hanahan, Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
19. R. Cao, E. Bråkenhielm, R. Pawliuk, D. Wariaro, M. J. Post, E. Wahlberg, P. Leboulch, Y. Cao, Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 9, 604-613 (2003).
20. L. J. Nissen, R. Cao, E. M. Hedlund, Z. Wang, X. Zhao, D. Wetterskog, K. Funa, E. Bråkenhielm, Y. Cao, Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 117, 2766-2777 (2007).
21. J. M. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, R. S. Kerbel, Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. U.S.A. 104, 17069-17074 (2007).
22. A. C. Richards Grayson, I. S. Choi, B. M. Tyler, P. P. Wang, H. Brem, M. J. Cima, R. Langer, Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat. Mater. 2, 767-772 (2003).
23. J. T. Santini Jr., M. J. Cima, R. Langer, A controlled-release microchip. Nature 397, 335-338 (1999).
24. R. K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001).
25. J. H. Prescott, S. Lipka, S. Baldwin, N. F. Sheppard Jr., J. M. Maloney, J. Coppeta, B. Yomtov, M. A. Staples, J. T. Santini Jr., Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat. Biotechnol. 24, 437-438 (2006).
26. A. Sanchez, R. K. Gupta, M. J. Alonso, G. R. Siber, R. Langer, Pulsed controlled-released system for potential use in vaccine delivery. J. Pharm. Sci. 85, 547-552 (1996).
27. P. G. Kibat, Y. Igari, M. A. Wheatley, H. N. Eisen, R. Langer, Enzymatically activated microencapsulated liposomes can provide pulsatile drug release. FASEB J. 4, 2533-2539 (1990).
28. S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto, Y. M. Kim, Y. Bdolah, K. H. Lim, H. T. Yuan, T. A. Libermann, I. E. Stillman, D. Roberts, P. A. D'Amore, F. H. Epstein, F. W. Sellke, R. Romero, V. P. Sukhatme, M. Letarte, S. A. Karumanchi, Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642-649 (2006). (Pubitemid 43865232)
29. T. T. Batchelor, A. G. Sorensen, E. di Tomaso, W. T. Zhang, D. G. Duda, K. S. Cohen, K. R. Kozak, D. P. Cahill, P. J. Chen, M. Zhu, M. Ancukiewicz, M. M. Mrugala, S. Plotkin, J. Drappatz, D. N. Louis, P. Ivy, D. T. Scadden, T. Benner, J. S. Loeffler, P. Y. Wen, R. K. Jain, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
30. J. Glade-Bender, J. J. Kandel, D. J. Yamashiro, VEGF blocking therapy in the treatment of cancer. Expert Opin. Biol. Ther. 3, 263-276 (2003).
31. R. K. Jain, Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
32. F. Winkler, S. V. Kozin, R. T. Tong, S. S. Chae, M. F. Booth, I. Garkavtsev, L. Xu, D. J. Hicklin, D. Fukumura, E. di Tomaso, L. L. Munn, R. K. Jain, Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004).
33. M. I. Dorrell, E. Aguilar, L. Scheppke, F. H. Barnett, M. Friedlander, Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 104, 967-972 (2007).
34. K. C. Wood, H. F. Chuang, R. D. Batten, D. M. Lynn, P. T. Hammond, Controlling interlayer diffusion to achieve sustained, multiagent delivery from layer-by-layer thin films. Proc. Natl. Acad. Sci. U.S.A. 103, 10207-10212 (2006).
35. R. S. Kerbel, Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Res. Treat. 39, 150-159 (2007).
36. M. A. Moses, H. Brem, R. Langer, Advancing the field of drug delivery: Taking aim at cancer. Cancer Cell 4, 337-341 (2003).
37. T. Kamba, D. M. McDonald, Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96, 1788-1795 (2007).
38. S. Faivre, G. Demetri, W. Sargent, E. Raymond, Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6, 734-745 (2007).
39. D. Ingber, T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru, H. Brem, J. Folkman, Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557 (1990).
40. R. Satchi-Fainaro, M. Puder, J. W. Davies, H. T. Tran, D. A. Sampson, A. K. Greene, G. Corfas, J. Folkman, Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10, 255-261 (2004).
41. R. B. Campbell, D. Fukumura, E. B. Brown, L. M. Mazzola, Y. Izumi, R. K. Jain, V. P. Torchilin, L. L. Munn, Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62, 6831-6836 (2002).
42. P. T. Jain, D. A. Gewirtz, Sustained enhancement of liposome-mediated gene delivery and gene expression in human breast tumour cells by ionizing radiation. Int. J. Radiat. Biol. 75, 217-223 (1999).
43. R. T. Tong, Y. Boucher, S. V. Kozin, F. Winkler, D. J. Hicklin, R. K. Jain, Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004).
44. T. Browder, C. E. Butterfield, B. M. Kräling, B. Shi, B. Marshall, M. S. O'Reilly, J. Folkman, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000).
45. D. Hanahan, G. Bergers, E. Bergsland, Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045-1047 (2000).
46. G. Klement, S. Baruchel, J. Rak, S. Man, K. Clark, D. J. Hicklin, P. Bohlen, R. S. Kerbel, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 (2000).
47. S. Dellapasqua, F. Bertolini, V. Bagnardi, E. Campagnoli, E. Scarano, R. Torrisi, Y. Shaked, P. Mancuso, A. Goldhirsch, A. Rocca, E. Pietri, M. Colleoni, Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26, 4899-4905 (2008).